Stocks · News reference
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.95) by 14.74 percent. This is a 28.24 percent decrease over losses of $(0.85) per
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
Read original at benzingaRBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
Read original at benzingaChardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
Read original at benzinga